PROGRAM FACULTY
Michelle Petri, MD, MPH
Professor of Medicine
Division of Rheumatology
Johns Hopkins University School of Medicine
Director, Hopkins Lupus Center
Baltimore, Maryland
Janet E. Pope, MD, MPH, FRCPC
Professor of Medicine
Division of Rheumatology
University of Western Ontario
London, Ontario, Canada
PROGRAM OVERVIEW
Systemic lupus erythematosus (SLE) is a burdensome autoimmune condition that affects multiple organ systems within the body. About half of patients with SLE develop lupus nephritis (LN), a serious kidney complication that is the leading cause of morbidity and mortality in patients with SLE. In this program, clinicians will learn strategies to diagnose SLE and LN earlier, minimize glucocorticoid toxicity, and evaluate clinical data and cases to guide treatment decisions.
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, rheumatology nurse practitioners (NPs), and physician assistants (PAs) involved in the management of SLE.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the clinical manifestations of SLE and the importance of early diagnosis and treatment to limit organ damage and disease activity
- Evaluate the mode of action, efficacy and safety of emerging treatment strategies for SLE management
- Apply a treat-to-target (T2T) approach involving formalized treatment, monitoring and treatment adjustment to help achieve the sequential goals of lowering disease activity followed by disease remission
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Michelle Petri, MD, MPH | Consultant fees: AbbVie, Alexion, Amgen, Annexon Biosciences, Architect Therapeutics, Astellas Pharma, AstraZeneca, Atara Biotherapeutics, Aurinia, Autolus Thearpeutics, Bain Capital, Baobab Therapeutics, Beeline Medicines, Biocryst, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Boxer Capital, Caribou Biosciences, CTI Clinical Trial and Consulting Services, Cullgen, CVS Health, Dianthus Therapeutics, DualityBio, Emergent Biosolutions, Enexa Bio, Ermium Therapeutics, Exo Therapeutics, Genentech, GentiBio, GSK, iCell Gene Therapeutics, Innovaderm Research, iTabMed, Kymera Therapeutics, Merck EMD Serono, Novartis, Owkin, Precision Biosciences, Regeneron, Santa Ana Bio, Seismic Therapeutic, Senti Biosciences, Steritas, Takeda, Tenet Medicines, TG Therapeutics, Variant Bio, Vertex Pharmaceuticals, Worldwide Clinical Trials, Zenas BioPharma Grant support: Aurinia, Exagen, GSK, Janssen |
| Janet E. Pope, MD, MPH, FRCPC |
Grants/Research: BMS, Janssen, Mallinckrodt, Pfizer (Seattle Genetics) Consultant: AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Boxer Capital, Bristol Myers Squibb, Celltrion Healthcare, Eli Lilly, Frensenius Kabi, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi Speaker/Advisory board: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Certa, Eli Lilly, Frensenius Kabi, Janssen, Nordic Pharma, Novartis, Organon, Otsuka, Palleon, Pfizer, Roche, Sandoz, Sanofi, UCB, Zura Data Safety and Monitoring Board: Astra Zeneca, Horizon, Novartis Other: RheumNow reporter, Around the Rheum (CRA) podcast, TREG international faculty |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Melissa Carter-Ozhan, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Dominique Barton, BS, BSN, has nothing to disclose.
- Sarah Milano, RN, MSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Director, Program Management for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 16, 2026
EXPIRATION DATE: October 16, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
